Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Myelodysplastic Syndromes 14Leukemia, Biphenotypic, Acute 14Recurrence 13Leukemia 12Burkitt Lymphoma 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 6Lymphoma, Mantle-Cell 5Neoplasm, Residual 4Myeloproliferative Disorders 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma, Myeloid 3Lymphoma, T-Cell 3Lymphoma 3Blast Crisis 3Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid 2Down Syndrome 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Targeted Therapy 1Pyloric Stenosis, Hypertrophic 1Neurofibromatosis 1 1Neoplasms by Histologic Type 1

Interventions

atezolizumab 3fludarabine 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Pemetrexed 2Nivolumab 2Cisplatin 2spartalizumab 1repotrectinib 1pertuzumab 1lutetium Lu 177 dotatate 1gilteritinib 1enzalutamide 1durvalumab 1copper dotatate CU-64 1cemiplimab 1Trastuzumab 1Sodium Chloride 1Radiotherapy 1Radiosurgery 1Mitomycin 1Lutetium-177 1Lutetium 1Injections 1Idarubicin 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasms by Histologic Type × Cytarabine × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡